Olon S.p.A. (hereinafter “Olon”), an Italian player among the world leaders in the manufacturing of Active Pharmaceutical Ingredients (APIs) and in providing Contract Development and Manufacturing (CDMO) services headquartered in Rodano (Milan), announces the acquisition of 100% of Capua BioServices S.p.A. (hereinafter “Capua BioServices”), one of the largest independently operating microbial fermentation-based contract manufacturers for the pharma and food industry based in Capua (Caserta), from Livia Group, an independent industrial holding based in Munich, Germany.
By integrating its relevant technical skills in the fields of chemical synthesis and fermentation, the international commercial network (US, EU, Asia) and the R&D capabilities with the experience and the technological know-how of Capua BioServices, Olon will strengthen its position as a global player in the pharma and CDMO industries, pursuing its growth plan and the enhancement of its technical expertise which led to the acquisition of important companies operating in the same field in recent years. This transaction restores the Italian ownership of an Italian entrepreneurial excellence, Capua BioServices, which will benefit from the competences, resources and international commercial network of Olon.
Paolo Tubertini, Olon CEO, declared: “In Capua Bioservices we have seen a high standing player which will add value to our activities. In a dynamic and very competitive field such as the pharma-chemicals and CDMO industries, it is crucial to have extensive, transversal and specialised competences. The acquisition of Capua BioServices is a strategic investment which, thanks to the new mix of capabilities, confirms the positioning of Olon as a world leader in the field of CDMO services for microbial fermentation. The confirmation of the workforce currently employed in Capua BioServices, so as to maximise the expertise, and significant investments in research and innovation will be the pillars of the growth plan which will be now pursued.”
With revenues in excess of 350 million euros in 2018 and ca. 1,500 employees (of which, more than 200 are in the R&D department), Olon is one of the main global players engaged in the pharma-chemicals and CDMO (Contract Development and Manufacturing Organization) business: it provides more than 250 APIs for the generic market and more than 60 between APIs and pharma intermediates to third parties. Headquartered in Rodano (Milan), Olon has 9 manufacturing facilities – 7 located in Northern Italy, 1 in Spain and 1 in the USA; and 4 foreign branch offices. Since 2016, the company has been pursuing an investment plan to develop its business and enlarge its production capacity, which resulted in the acquisition of INFA Group, followed by the acquisition of the Chemical Division of Ricerca Biosciences, located in the USA; moreover, it has recently signed an agreement to acquire a production plant in India.
